glp-1 incretin effect GLP-1: Actions on Beta-cell Mass and Function The Generation and Function of

These medications facilitate weight loss by enhancing feelings of fullness and stabilizing blood sugar levels

Activation of glucagon-like peptide-1 receptors and skilled reach foraging

A May 2026 Lancet trial found semaglutide reduced heavy drinking days by 41% versus 26% on placebo in patients with alcohol use disorder and obesity, but the drug is not FDA-approved for this use

Questions include dose-specific effects of single nutrient, food, and dietary pattern interventions

Non-alcoholic steatohepatitis or NASH is defined as macrovesicular steatosis with inflammatory changes and cellular injury with hepatocellular ballooning, with or without fibrosis

In reality, while these medications are designed to work on the same biological pathway, they function quite differently from the GLP-1 your body naturally produces after a meal